Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer
{{output}}
Targeting programmed death 1(PD-1) has been approved for relapsed cervical cancer with unsatisfactory clinical efficacy. This study aims to analyse the impact of PI3K pathway activation on tumour immune microenvironment and evaluates the immune sensitization e... ...
